Literature DB >> 1333176

No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis.

A Svenningsson1, J Lycke, B Svennerholm, S Gronowitz, O Andersen.   

Abstract

Polymerase chain reaction analysis was used to investigate the possible role of human spumaretrovirus and oncoretroviruses (human T-cell lymphotropic virus types I [HTLV-I] and II [HTLV-II]) in multiple sclerosis. Eleven patients with relapsing-remitting multiple sclerosis in exacerbation and 11 normal blood donors were included in the study. Cerebrospinal fluid cells, peripheral blood mononuclear cells, and plasma were cocultured with allogeneic mononuclear cells for 6 weeks. Cultured cells were subjected to polymerase chain reaction analysis with primers selected for the pol and gag (human spumaretrovirus), pol and env (HTLV-I), and pol (HTLV-II) genes. Polymerase chain reaction was negative in all patient and blood donor control samples, whereas positive controls were consistently reactive with high sensitivity. No culture exhibited cytopathic effects and supernatants were negative for reverse transcriptase activity. Thus, our results do not support a role for these retroviruses in the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333176     DOI: 10.1002/ana.410320518

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

Review 1.  Historical perspective of foamy virus epidemiology and infection.

Authors:  C D Meiering; M L Linial
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

2.  Isolation and growth of a cytopathic agent from multiple sclerosis brain tissue.

Authors:  Anthony R White; Nichole S Dutton; Robert D Cook
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

3.  Human spumaretrovirus antibody reactivity in multiple sclerosis.

Authors:  J Lycke; B Svennerholm; A Svenningsson; W Muranyi; R M Flügel; O Andersen
Journal:  J Neurol       Date:  1994-02       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.